SELLAS Life Sciences Group, Inc. Business Acquisition, Purchase Price Allocation, Goodwill Amount (Deprecated 2013-01-31)
SELLAS Life Sciences Group, Inc. (SLS) had Business Acquisition, Purchase Price Allocation, Goodwill Amount (Deprecated 2013-01-31) of $5.90 million as of 2012-12-31, per its 10-K filed 2013-03-12.
Discontinued › Notes › Business Combinations
us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillAmount · last filed 2014-03-17
- 2012-12-31: Business Acquisition, Purchase Price Allocation, Goodwill Amount (Deprecated 2013-01-31) $5.90M.
- 2012-06-30: Business Acquisition, Purchase Price Allocation, Goodwill Amount (Deprecated 2013-01-31) $5.90M.
- 2011-12-31: Business Acquisition, Purchase Price Allocation, Goodwill Amount (Deprecated 2013-01-31) $5.90M.
- 2011-09-30: Business Acquisition, Purchase Price Allocation, Goodwill Amount (Deprecated 2013-01-31) $5.90M.
| Period end | Business Acquisition, Purchase Price Allocation, Goodwill Amount (Deprecated 2013-01-31) |
|---|---|
| 2012-12-31 | $5.90M 10-K · filed 2013-03-12 |
| 2012-06-30 | $5.90M 10-Q · filed 2012-08-14 |
| 2011-12-31 | $5.90M 10-K · filed 2014-03-17 |
| 2011-09-30 | $5.90M 10-Q · filed 2012-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |